



Revance Therapeutics  
Investor Relations Department  
7555 Gateway Boulevard  
Newark, CA 94560  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: RVNC

Last Trade:	24.55
Trade Time:	4:00 PM ET Nov 21, 2017
Change:	-0.05  (-0.203%)
Day Range	24.50 - 25.00
52-Week Range	15.85 - 28.75
Volume	199,696

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.


## Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology.

Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Nov 20, 2017

[Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia](#)

Nov 2, 2017

[Revance Releases Third Quarter 2017 Results](#)

Oct 18, 2017

[Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017](#)

Oct 18, 2017

[Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis](#)

Sep 19, 2017

[Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

Feb 28, 2017

[Annual Report \(10-K\)](#)

Mar 24, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 3, 2017

[Quarterly Report \(10-Q\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)